Phase II Trial of Combined Modality Treatment in Primary Central Nervous System Lymphoma

Lymphoma, B Cell Clinical Trial

Official title:
Randomized Phase II Trial on Primary Chemotherapy With High-dose Methotrexate, Alone or Associated With High-dose Cytarabine, Followed by Response- and Age-tailored Radiotherapy for Immunocompetent Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

Status Completed

Clinical Trial Summary

Aim of the study is to establish in a prospective, randomized clinical trial the activity of primary chemotherapy containing high dose-methotrexate, alone or combined with high dose cytarabine, in patients with primary central nervous system lymphoma

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00210314
Study type	Interventional
Source	International Extranodal Lymphoma Study Group (IELSG)
Contact
Status	Completed
Phase	Phase 2
Start date	July 2003
Completion date	December 2007

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00210379` - Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's Lymphoma	Phase 2
Terminated	`NCT00523939` - DepoCyt for Active Lymphomatous or Leukemic Meningitis	Phase 2
Completed	`NCT02679196` - The Safety, Pharmacokinetic and Pharmacodynamic Effect of KA2237 (PI3 Kinase p110β/δ Inhibitor) In B Cell Lymphoma	Phase 1
Not yet recruiting	`NCT02992834` - Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma	Phase 4
Withdrawn	`NCT00210340` - A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis	Phase 1